Assoc.Prof.MORISHITA

• Associate Professor (Clinical Professer)
  • Asahiro MORISHITA, M.D., Ph.D.
• Visiting Associate Professor
  • Kiyoyuki KOBAYASHI, M.D., Ph.D.

  1. Research on the pathophysiology and treatment of MAFLD / MASH
  2. Research on the pathophysiology and treatment for hepatocellular carcinoma
  3. Research on endoscopic diagnosis and treatment for biliary and pancreatic diseases
  4. Research on the pathophysiology and treatment of the onset of biliary tract cancer and pancreatic cancer

• Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response
  to atezolizumab plus bevacizumab in hepatocellular carcinoma. Oura K, Morishita
  A, et al. J Gastroenterol. 2025 Apr 3.
• Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by
  metabolic dysfunction-associated steatotic liver disease: A multicentre study.
  Fukunaga K, Morishita A, et al. Diabetes Obes Metab. 2025 Mar;27(3):1498-
  1506.
• Adverse events as potential predictive factors of therapeutic activity in patients
  with unresectable hepatocellular carcinoma treated with atezolizumab plus
  bevacizumab. Tada T, Morishita A, et al. Cancer Med. 2023 Apr;12(7):7772-7783.